Business
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027 Cash and investments of $393.3 million as of March 31, 2026; runway into 2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biophar
About this update from Cullinan Therapeutics, Inc.
[{"type":"image","alt":"Cullinan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cullinan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/1cff5107b9e855d76a3c4673aa371813"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tnwVBkJRj4wHwYFGuVIm8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxOA--/https://media.zenfs.com/en/globenewswire.com/1cff5107b9e855d76a3c4673aa371813","width":300,"height":156},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/tnwVBkJRj4wHwYFGuVIm8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxOA--/https://media.zenfs.com/en/globenewswire.com/1cff5107b9e855d76a3c4673aa371813","width":300,"height":156}},"lazy":false},{"type":"text","content":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 ","length":173,"tagName":"p"},{"type":"text","content":"Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027","length":116,"tagName":"p"},{"type":"text","content":"Cash and investments of $393.3 million as of March 31, 2026; runway into 2029","length":77,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided an update on recent and anticipated business highlights and announced its financial results for the first quarter ended March 31, 2026.","length":405,"tagName":"p"},{"type":"text","content":"“T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modality. We look forward to sharing initial clinical data for CLN-978 and velinotamig throughout 2026. CD19 and BCMA are now well-validated autoimmune targets, and by addressing both, we aim to comprehensively treat more diseases and redefine standards of care for more patients with these two clinical-stage programs. Similarly, the early success of CLN-049 in AML further reinforces the remarkable promise of T ...